{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:40Z","timestamp":1786987780399,"version":"build-2736575974"},"reference-count":439,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.disamonth.2022.101484","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:22:22Z","timestamp":1665271342000},"page":"101484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols"],"prefix":"10.1016","volume":"69","author":[{"given":"Harshank","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui Rakesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya Rakeshkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya","family":"Avanthika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunj","family":"Gor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0001","first-page":"277","article-title":"[published correction appears in Am J Respir Crit Care Med2002 Aug 1;166(3):426]","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccm.2004.08.003","article-title":"Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects","volume":"25","author":"Brown","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40248-019-0197-0","article-title":"Clinical course and management of idiopathic pulmonary fibrosis","volume":"14","author":"Quinn","year":"2019","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0004","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.disamonth.2022.101484_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1753465816686743","article-title":"Optimizing quality of life in patients with idiopathic pulmonary fibrosis","volume":"11","author":"van Manen","year":"2017","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","article-title":"The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0007","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0008","first-page":"73","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis","volume":"6","author":"Aburto","year":"2018","journal-title":"Med Sci (Basel)"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0009","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","article-title":"Inflammation and immunity in IPF pathogenesis and treatment","volume":"147","author":"Heukels","year":"2019","journal-title":"Respir Med"},{"issue":"153","key":"10.1016\/j.disamonth.2022.101484_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0029-2019","article-title":"What have we learned from basic science studies on idiopathic pulmonary fibrosis?","volume":"28","author":"Yanagihara","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0012","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2017","article-title":"Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study","volume":"50","author":"Walsh","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0014","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/resp.12683","article-title":"Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history","volume":"21","author":"Sgalla","year":"2016","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01603-2017","article-title":"Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001-2013","volume":"51","author":"Marshall","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0016","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1183\/09031936.00163814","article-title":"The genetic basis of idiopathic pulmonary fibrosis","volume":"45","author":"Kropski","year":"2015","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.disamonth.2022.101484_bib0017","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2014 Sep 18;371(12):1172]","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.disamonth.2022.101484_bib0018","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [published correction appears in N Engl J Med. 2015 Aug 20;373(8):782]","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0019","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course, and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"9807","key":"10.1016\/j.disamonth.2022.101484_bib0020","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0021","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0022","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0023","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence, and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0024","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-2466-13-53","article-title":"Idiopathic pulmonary fibrosis\u2013a systematic review on methodology for the collection of epidemiological data","volume":"13","author":"Kaunisto","year":"2013","journal-title":"BMC Pulm Med"},{"issue":"137","key":"10.1016\/j.disamonth.2022.101484_bib0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1183\/16000617.0040-2015","article-title":"Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation","volume":"24","author":"Caminati","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.disamonth.2022.101484_bib0026","first-page":"810","article-title":"Incidence, and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"AJRCCM"},{"issue":"10082","key":"10.1016\/j.disamonth.2022.101484_bib0027","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0025-6196(11)62955-8","article-title":"Idiopathic pulmonary fibrosis in patients younger than 50 years","volume":"80","author":"Nadrous","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0029","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/thoraxjnl-2016-209172","article-title":"Pulmonary fibrosis in the era of stratified medicine","volume":"71","author":"Mathai","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.disamonth.2022.101484_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/CLEP.S54815","article-title":"Epidemiology of idiopathic pulmonary fibrosis","volume":"5","author":"Ley","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0031","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1183\/13993003.01504-2015","article-title":"Epidemiology, and survival of idiopathic pulmonary fibrosis from national data in Canada","volume":"48","author":"Hopkins","year":"2016","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0032","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11 [published correction appears in Lancet Respir Med. 2014 Jul;2(7):e12]","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0033","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1164\/rccm.201504-0818OC","article-title":"Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation","volume":"192","author":"Esposito","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"126","key":"10.1016\/j.disamonth.2022.101484_bib0034","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1183\/09059180.00002512","article-title":"Incidence, and prevalence of idiopathic pulmonary fibrosis: review of the literature","volume":"21","author":"Nalysnyk","year":"2012","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0035","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1590\/s1806-37562015000000165","article-title":"How many patients with idiopathic pulmonary fibrosis are there in Brazil? [published correction appears in J Bras Pneumol. 2016 Jan-Feb;42(1):78]","volume":"41","author":"Baddini-Martinez","year":"2015","journal-title":"J Bras Pneumol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0036","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","article-title":"Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK","volume":"35","author":"Strongman","year":"2018","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0037","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","article-title":"Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences","volume":"190","author":"Natsuizaka","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0038","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chest.2020.02.009","article-title":"Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study","volume":"158","author":"Zaman","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.disamonth.2022.101484_bib0039","article-title":"Epidemiology of Idiopathic Pulmonary Fibrosis","author":"Patil","year":"2021","journal-title":"Idiopathic Pulmonary Fibrosis [Working Title]"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0040","first-page":"71","article-title":"Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis","volume":"5","author":"McGee","year":"2014","journal-title":"Int J Mol Epidemiol Genet"},{"key":"10.1016\/j.disamonth.2022.101484_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111473","article-title":"Understanding idiopathic pulmonary fibrosis - Clinical features, molecular mechanism, and therapies","volume":"153","author":"Suri","year":"2021","journal-title":"Exp Gerontol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0042","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1600-6143.2005.01205.x","article-title":"Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis","volume":"6","author":"Lederer","year":"2006","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0043","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1600-6143.2006.01480.x","article-title":"Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS\/OPTN database analysis","volume":"6","author":"Lederer","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.disamonth.2022.101484_bib0044","article-title":"Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy [published online ahead of print, 2017 Jul 5]","author":"Leuschner","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/icvts\/ivab237","article-title":"Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?","volume":"34","author":"Zhu","year":"2022","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0046","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0047","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/thoraxjnl-2019-214478","article-title":"Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study","volume":"75","author":"Abramson","year":"2020","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0048","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12931-017-0642-6","article-title":"Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis","volume":"18","author":"K\u00e4rkk\u00e4inen","year":"2017","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0049","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.201902-0431CI","article-title":"Patient Registries in Idiopathic Pulmonary Fibrosis","volume":"200","author":"Culver","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0050","series-title":"Stat Pearls","article-title":"Idiopathic Pulmonary Fibrosis","author":"Krishna","year":"2021"},{"key":"10.1016\/j.disamonth.2022.101484_bib0051","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1513\/pats.200512-131TK","article-title":"Is idiopathic pulmonary fibrosis an environmental disease?","volume":"3","author":"Taskar","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0052","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41598-021-81591-z","article-title":"Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.disamonth.2022.101484_bib0053","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/808260","article-title":"Smoking and idiopathic pulmonary fibrosis","volume":"2012","author":"Oh","year":"2012","journal-title":"Pulm Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0054","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/thoraxjnl-2017-209967","article-title":"Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis","volume":"73","author":"Ses\u00e9","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.chest.2018.01.015","article-title":"Air Pollution Exposure Is Associated with Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis","volume":"154","author":"Johannson","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0056","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S2213-2600(14)70069-4","article-title":"Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study [published correction appears in Lancet Respir Med. 2014 Aug;2(8):e14]","volume":"2","author":"Han","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0057","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1164\/rccm.201403-0541OC","article-title":"The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis","volume":"190","author":"Molyneaux","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0058","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.chest.2019.10.032","article-title":"Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis","volume":"157","author":"Sheng","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0059","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.chest.2018.07.038","article-title":"Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis","volume":"155","author":"B\u00e9dard M\u00e9thot","year":"2019","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101484_bib0060","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0061","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.rmed.2011.08.022","article-title":"Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Garc\u00eda-Sancho","year":"2011","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0062","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30007-9","article-title":"Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?","volume":"6","author":"Wolters","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0063","doi-asserted-by":"crossref","first-page":"24007","DOI":"10.1038\/s41598-021-03533-z","article-title":"The minor T allele of the MUC5B promoter rs35705950 associated with susceptibility to idiopathic pulmonary fibrosis: a meta-analysis","volume":"11","author":"Wu","year":"2021","journal-title":"Sci Rep"},{"issue":"3 Suppl","key":"10.1016\/j.disamonth.2022.101484_bib0064","first-page":"S47","article-title":"Pulmonary fibrosis in families","volume":"29","author":"Loyd","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-018-0730-2","article-title":"Idiopathic pulmonary fibrosis: pathogenesis and management","volume":"19","author":"Sgalla","year":"2018","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0066","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","article-title":"Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model","volume":"189","author":"Selman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0067","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.matbio.2018.03.021","article-title":"Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets","volume":"71-72","author":"Hewlett","year":"2018","journal-title":"Matrix Biol"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0068","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bbadis.2013.03.001","article-title":"Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis","volume":"1832","author":"Sakai","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0069","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1165\/rcmb.2020-0303OC","article-title":"Targeting the AXL Receptor in Combating Smoking-related Pulmonary Fibrosis","volume":"64","author":"Yang","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135266","article-title":"Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-\u03b2 Induced Myofibroblast Differentiation via Prostaglandin E2","volume":"10","author":"Epa","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0071","first-page":"5","article-title":"Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) inductions","volume":"16","author":"Freeburn","year":"2005","journal-title":"Eur Cytokine Netw"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0072","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1164\/rccm.201810-1975TR","article-title":"Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases","volume":"200","author":"Barnes","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0073","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1183\/09031936.00060708","article-title":"MMP expression and abnormal lung permeability are important determinants of outcome in IPF","volume":"33","author":"McKeown","year":"2009","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0074","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00259-019-04586-z","article-title":"Clinical quantification of the integrin \u03b1v\u03b26 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lungs (PETAL Study)","volume":"47","author":"Lukey","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-021-01863-0","article-title":"Dual inhibition of \u03b1v\u03b26 and \u03b1v\u03b21 reduces fibrogenesis in lung tissue explants from patients with IPF","volume":"22","author":"Decaris","year":"2021","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0076","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1513\/pats.201202-017AW","article-title":"Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast","volume":"9","author":"Hinz","year":"2012","journal-title":"Proc Am Thorac Soc"},{"issue":"19","key":"10.1016\/j.disamonth.2022.101484_bib0077","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0078","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","article-title":"Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0079","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143226","article-title":"Immune dysregulation as a driver of idiopathic pulmonary fibrosis","volume":"131","author":"Shenderov","year":"2021","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0080","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.1203476","article-title":"Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients","volume":"191","author":"Xue","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0081","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/ijms23010546","article-title":"Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?","volume":"23","author":"Avci","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2022.101484_bib0082","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cbpa.2019.01.024","article-title":"The roles of microRNAs in epigenetic regulation","volume":"51","author":"Yao","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.disamonth.2022.101484_bib0083","doi-asserted-by":"crossref","unstructured":"Kishaba T. Evaluation and management of Idiopathic Pulmonary Fibrosis. Respir Investig. 2019;57(4):300-311. doi:10.1016\/j.resinv.2019.02.003","DOI":"10.1016\/j.resinv.2019.02.003"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0084","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.resinv.2020.04.002","article-title":"Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches","volume":"58","author":"Glass","year":"2020","journal-title":"Respir Investig"},{"issue":"12 Pt 1","key":"10.1016\/j.disamonth.2022.101484_bib0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00005","article-title":"The clinical course of patients with idiopathic pulmonary fibrosis","volume":"142","author":"Martinez","year":"2005","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0086","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5858\/arpa.2015-0288-SA","article-title":"Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally","volume":"140","author":"Smith","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0087","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0088","series-title":"StatPearls [Internet]","article-title":"Idiopathic Pulmonary Fibrosis","author":"Krishna","year":"2022"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0089","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.rmed.2014.03.008","article-title":"Idiopathic pulmonary fibrosis: early detection and referral","volume":"108","author":"Oldham","year":"2014","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1164\/ajrccm.186.3.289","article-title":"Subclinical interstitial lung disease: no place for crackles?","volume":"186","author":"Cottin","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0091","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1183\/09031936.00001612","article-title":"Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis?","volume":"40","author":"Cottin","year":"2012","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0092","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/jclinpath-2013-201442","article-title":"Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology","volume":"66","author":"Smith","year":"2013","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0093","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thx.52.1.38","article-title":"British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society","volume":"52","author":"Johnston","year":"1997","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0094","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1378\/chest.10-2572","article-title":"Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium","volume":"140","author":"Nathan","year":"2011","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0095","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm.164.6.2001056","article-title":"Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0096","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1378\/chest.13-0844","article-title":"Predicting pulmonary fibrosis disease course from past trends in pulmonary function","volume":"145","author":"Schmidt","year":"2014","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0097","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0025-6196(11)60966-X","article-title":"Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease","volume":"82","author":"Aduen","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0098","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.200210-1245OC","article-title":"Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends","volume":"168","author":"Latsi","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0099","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","article-title":"Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0101","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0102","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/ajrccm.164.7.2003140","article-title":"Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"4 Pt 1","key":"10.1016\/j.disamonth.2022.101484_bib0103","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1164\/ajrccm.161.4.9907002","article-title":"Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival","volume":"161","author":"Douglas","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0104","doi-asserted-by":"crossref","unstructured":"Gaillard, F. Idiopathic pulmonary fibrosis. Case study, Radiopaedia.org. (accessed on 07 Aug 2022) https:\/\/doi.org\/10.53347\/rID-14207","DOI":"10.53347\/rID-14207"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/labinvest.2011.80","article-title":"Absence of Thy-1 results in TGF-\u03b2 induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts","volume":"91","author":"Ram\u00edrez","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.disamonth.2022.101484_bib0106","series-title":"Interstitial Lung Disease. Shelton","first-page":"895","article-title":"Idiopathic pulmonary fibrosis","author":"King","year":"2011"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12890-018-0643-3","article-title":"Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights","volume":"18","author":"Faverio","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"133","key":"10.1016\/j.disamonth.2022.101484_bib0108","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1183\/09059180.00004914","article-title":"Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? [published correction appears in Eur Respir Rev. 2014 Dec 23(134):537]","volume":"23","author":"Wuyts","year":"2014","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0109","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","article-title":"Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go","volume":"196","author":"Salisbury","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0110","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","article-title":"Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management","volume":"196","author":"Vasakova","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0111","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.6061\/clinics\/2019\/e225","article-title":"Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics","volume":"74","author":"Hochhegger","year":"2019","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0112","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1164\/rccm.201208-1544CI","article-title":"Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature","volume":"188","author":"Hodnett","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0113","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5858\/134.3.462","article-title":"Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society","volume":"134","author":"Roggli","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0114","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/his.12951","article-title":"Usual interstitial pneumonia in asbestos-exposed cohorts - concurrent idiopathic pulmonary fibrosis or atypical asbestosis?","volume":"69","author":"Attanoos","year":"2016","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0115","first-page":"1839","article-title":"Pulmonary Fibrosis in Hermansky-Pudlak Syndrome [published correction appears in Ann Am Thorac Soc. 2017 Jan;14(1):152]","volume":"13","author":"Vicary","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0116","first-page":"951","article-title":"Pneumopathies interstitielles iatrog\u00e9niques [Drug-induced interstitial lung diseases]","volume":"64","author":"Bonniaud","year":"2014","journal-title":"Rev Prat"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0117","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5858\/arpa.2012-0225-RA","article-title":"Update for pathologists on idiopathic interstitial pneumonias","volume":"136","author":"Larsen","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0118","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1148\/radiol.2453061881","article-title":"Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT","volume":"246","author":"Silva","year":"2008","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0119","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/crj.12224","article-title":"Autoimmune symptoms in idiopathic pulmonary fibrosis: clinical significance","volume":"10","author":"Alhamad","year":"2016","journal-title":"Clin Respir J"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1378\/chest.14-1049","article-title":"Aspiration-related pulmonary syndromes","volume":"147","author":"Hu","year":"2015","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0121","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1148\/radiol.2213010158","article-title":"Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT","volume":"221","author":"MacDonald","year":"2001","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0122","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rmed.2015.02.002","article-title":"Natural history of idiopathic pulmonary fibrosis","volume":"109","author":"Kim","year":"2015","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0123","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0124","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1164\/rccm.200209-1112OC","article-title":"Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia","volume":"168","author":"Flaherty","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CPM.0000000000000031","article-title":"The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis","volume":"21","author":"Lee","year":"2014","journal-title":"Clin Pulm Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"Suppl s1","key":"10.1016\/j.disamonth.2022.101484_bib0127","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/ajt.15677","article-title":"OPTN\/SRTR 2018 Annual Data Report: Lung","volume":"20","author":"Valapour","year":"2020","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0128","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1183\/09031936.00099614","article-title":"Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study","volume":"44","author":"Dalleywater","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0129","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2213-2600(16)30325-3","article-title":"The diagnosis of idiopathic pulmonary fibrosis: current and future approaches","volume":"5","author":"Martinez","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0131","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0132","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/ajt.14081","article-title":"Effect of Lung Transplantation on Health-Related Quality of Life in the Era of the Lung Allocation Score: A U.S. Prospective Cohort Study","volume":"17","author":"Singer","year":"2017","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0133","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/j.1600-6143.2009.02613.x","article-title":"Disease-specific survival benefit of lung transplantation in adults: a national cohort study","volume":"9","author":"Titman","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u2013an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2020.104026","article-title":"Lung transplantation for idiopathic pulmonary fibrosis","volume":"49","author":"Le Pavec","year":"2020","journal-title":"Presse Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0136","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11739-019-02195-0","article-title":"Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care","volume":"15","author":"Harari","year":"2020","journal-title":"Intern Emerg Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0137","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjms.2019.02.013","article-title":"Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes","volume":"357","author":"Wakwaya","year":"2019","journal-title":"Am J Med Sci"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0138","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.rmed.2007.07.012","article-title":"The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK","volume":"101","author":"Le Jeune","year":"2007","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0139","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMra003200","article-title":"Idiopathic pulmonary fibrosis","volume":"345","author":"Gross","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/resp.12683","article-title":"Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history","volume":"21","author":"Sgalla","year":"2016","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0141","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy","volume":"134","author":"Selman","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0142","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01699-2018","article-title":"Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors","volume":"53","author":"Sack","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0143","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1164\/rccm.200408-1104OC","article-title":"Clinical and pathologic features of familial interstitial pneumonia","volume":"172","author":"Steele","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"6759","key":"10.1016\/j.disamonth.2022.101484_bib0144","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/bmj.301.6759.1015","article-title":"What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust","volume":"301","author":"Scott","year":"1990","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0145","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1055\/s-0028-1101277","article-title":"Exposures and idiopathic lung disease","volume":"29","author":"Taskar","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0146","first-page":"107","article-title":"Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Egypt: a multicenter case-control study","volume":"3","author":"Awadalla","year":"2012","journal-title":"Int J Occup Environ Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0147","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/aje\/152.4.307","article-title":"Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers","volume":"152","author":"Baumgartner","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0148","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1164\/ajrccm.150.3.8087336","article-title":"Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure","volume":"150","author":"Iwai","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0149","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00559-2017","article-title":"Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study","volume":"50","author":"Sack","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0150","doi-asserted-by":"crossref","first-page":"XIII","DOI":"10.1016\/S0272-5231(03)00146-1","article-title":"Iatrogenic lung disease","volume":"25","author":"Camus","year":"2004","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0151","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0272-5231(03)00138-2","article-title":"Pathologic characteristics of drug-induced lung disease","volume":"25","author":"Flieder","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0152","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0153","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2147\/TCRM.S184291","article-title":"Idiopathic pulmonary fibrosis and GERD: links and risks","volume":"15","author":"Ghisa","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"129","key":"10.1016\/j.disamonth.2022.101484_bib0154","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1183\/09059180.00000713","article-title":"The role of infection in the pathogenesis of idiopathic pulmonary fibrosis","volume":"22","author":"Molyneaux","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0155","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1164\/ajrccm\/146.1.266","article-title":"Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus","volume":"146","author":"Ueda","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0156","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/thx.51.3.315","article-title":"Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis","volume":"51","author":"Meliconi","year":"1996","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0157","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1378\/chest.14-0976","article-title":"CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis","volume":"147","author":"Chung","year":"2015","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0158","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/13993003.01680-2015","article-title":"Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia","volume":"47","author":"Yagihashi","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0159","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00004728-200303000-00028","article-title":"Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease","volume":"27","author":"Remy-Jardin","year":"2003","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejrad.2013.05.012","article-title":"Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis","volume":"83","author":"Johkoh","year":"2014","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0161","doi-asserted-by":"crossref","first-page":"W235","DOI":"10.2214\/AJR.12.9569","article-title":"Sinogram-affirmed iterative reconstruction of low-dose chest CT: effect on image quality and radiation dose","volume":"201","author":"Kalra","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0162","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/RTI.0b013e3181c227b2","article-title":"CT evaluation of diffuse infiltrative lung disease: dose considerations and optimal technique","volume":"24","author":"Mayo","year":"2009","journal-title":"J Thorac Imaging"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0163","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.2021200279","article-title":"Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation","volume":"3","author":"Hobbs","year":"2021","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0164","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s00330-014-3559-1","article-title":"Chest CT using spectral filtration: radiation dose, image quality, and spectrum of clinical utility","volume":"25","author":"Braun","year":"2015","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0165","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/0284185113512300","article-title":"Utility of expiratory thin-section CT for fibrotic interstitial pneumonia","volume":"55","author":"Tokura","year":"2014","journal-title":"Acta Radiol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0166","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1148\/radiol.10092307","article-title":"Thin-section CT of the lungs: the Hinterland of normal [published correction appears in Radiology. 2010 Dec;257(3):897]","volume":"256","author":"Hansell","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.disamonth.2022.101484_bib0167","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejrad.2017.03.018","article-title":"Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern","volume":"91","author":"Kim","year":"2017","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0168","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner Society: glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0169","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.200611-1696OC","article-title":"Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival","volume":"177","author":"Sumikawa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2483071378","article-title":"Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study","volume":"249","author":"Shin","year":"2008","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0171","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/resp.12531","article-title":"HRCT of fibrosing lung disease","volume":"20","author":"Jacob","year":"2015","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0172","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2214\/AJR.15.14525","article-title":"Diagnosis of Usual Interstitial Pneumonitis in the Absence of Honeycombing: Evaluation of Specific CT Criteria With Clinical Follow-Up in 38 Patients","volume":"206","author":"Gruden","year":"2016","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0173","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1148\/radiol.12112516","article-title":"Interobserver variability in the CT assessment of honeycombing in the lungs","volume":"266","author":"Watadani","year":"2013","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0174","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2214\/AJR.07.3177","article-title":"Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings","volume":"191","author":"Sundaram","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.08-2306","article-title":"Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension","volume":"136","author":"Mej\u00eda","year":"2009","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0176","first-page":"257","article-title":"The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis","volume":"51","author":"Mura","year":"2006","journal-title":"Respir Care"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0177","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/pin.12054","article-title":"Airspace enlargement with fibrosis shows characteristic histology and immunohistology different from usual interstitial pneumonia, nonspecific interstitial pneumonia and centrilobular emphysema","volume":"63","author":"Yamada","year":"2013","journal-title":"Pathol Int"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0178","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ejrad.2015.01.015","article-title":"Multiple, thin-walled cysts are one of the HRCT features of airspace enlargement with fibrosis","volume":"84","author":"Watanabe","year":"2015","journal-title":"Eur J Radiol"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0179","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00330-011-2098-2","article-title":"Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality","volume":"21","author":"Edey","year":"2011","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0180","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1148\/radiology.189.3.8234692","article-title":"Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation","volume":"189","author":"Remy-Jardin","year":"1993","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0181","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2214\/AJR.04.1663","article-title":"Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients","volume":"186","author":"Souza","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0182","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00330-005-2671-7","article-title":"Disseminated dendriform pulmonary ossification associated with usual interstitial pneumonia: incidence and thin-section CT-pathologic correlation","volume":"15","author":"Kim","year":"2005","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0183","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1148\/radiol.2017152419","article-title":"Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations","volume":"284","author":"Egashira","year":"2017","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0184","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1378\/chest.124.4.1215","article-title":"Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia","volume":"124","author":"Hunninghake","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0185","doi-asserted-by":"crossref","first-page":"W458","DOI":"10.2214\/AJR.12.9437","article-title":"UIP diagnosed at surgical lung biopsy, 2000-2009: HRCT patterns and proposed classification system","volume":"200","author":"Gruden","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0186","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/thx.2010.137190","article-title":"Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease","volume":"66","author":"Tcherakian","year":"2011","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0187","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1148\/radiology.211.2.r99ma01555","article-title":"Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients","volume":"211","author":"Johkoh","year":"1999","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0188","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1148\/radiology.205.1.9314990","article-title":"Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung","volume":"205","author":"Swensen","year":"1997","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0189","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1164\/ajrccm.164.2.2101090","article-title":"Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis","volume":"164","author":"Hunninghake","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1148\/radiology.171.1.2928513","article-title":"Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography","volume":"171","author":"Mathieson","year":"1989","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0191","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1378\/chest.116.5.1168","article-title":"The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study","volume":"116","author":"Raghu","year":"1999","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0192","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2213-2600(14)70011-6","article-title":"Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0193","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/thoraxjnl-2016-209671","article-title":"The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia","volume":"72","author":"Brownell","year":"2017","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0194","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200906-0959OC","article-title":"Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis","volume":"181","author":"Fell","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1164\/rccm.200412-1756OC","article-title":"High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis","volume":"172","author":"Lynch","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0196","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1148\/radiol.0990898","article-title":"Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses","volume":"254","author":"Sverzellati","year":"2010","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0197","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","article-title":"Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis","volume":"178","author":"Akira","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0198","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1164\/ajrccm.164.2.2105010a","article-title":"Idiopathic pulmonary fibrosis: to biopsy or not to biopsy","volume":"164","author":"Katzenstein","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0199","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00023-2019","article-title":"Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?","volume":"53","author":"Hutchinson","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2214\/AJR.15.15674","article-title":"CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond","volume":"206","author":"Gruden","year":"2016","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0201","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1378\/chest.127.5.1600","article-title":"Outcomes and safety of surgical lung biopsy for interstitial lung disease","volume":"127","author":"Lettieri","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0202","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.arbres.2011.11.002","article-title":"Video-assisted thoracoscopic lung biopsy in the diagnosis of interstitial lung disease: a prospective, multi-center study in 224 patients","volume":"48","author":"Fibla","year":"2012","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0203","first-page":"3","article-title":"Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy","volume":"30","author":"Nguyen","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0204","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.chest.2016.06.019","article-title":"Surgical Lung Biopsy for Interstitial Lung Diseases","volume":"151","author":"Raj","year":"2017","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0205","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jtcvs.2014.12.057","article-title":"Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: A systematic review and meta-analysis","volume":"149","author":"Han","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0206","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1378\/chest.128.4.2375","article-title":"Thoracoscopic lung biopsy is a safe procedure in diagnosing usual interstitial pneumonia","volume":"128","author":"Tiitto","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0207","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.01.17201750","article-title":"High short-term mortality following lung biopsy for usual interstitial pneumonia","volume":"17","author":"Utz","year":"2001","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0208","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.125.2.522","article-title":"Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias","volume":"125","author":"Monaghan","year":"2004","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0209","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1164\/ajrccm.164.9.2103074","article-title":"Histopathologic variability in usual and nonspecific interstitial pneumonias","volume":"164","author":"Flaherty","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1010-7940(02)00021-0","article-title":"Does lung biopsy help patients with interstitial lung disease?","volume":"21","author":"Qureshi","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0211","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","article-title":"In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011","volume":"193","author":"Hutchinson","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0212","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1513\/AnnalsATS.202006-759OC","article-title":"Surgical Lung Biopsy for Interstitial Lung Disease. Safety and Feasibility at a Tertiary Referral Center","volume":"18","author":"Pastre","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0213","first-page":"109","volume":"89","author":"Yang","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0214","first-page":"1828","article-title":"Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease. A Systematic Review and Metaanalysis","volume":"13","author":"Johannson","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0215","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1164\/rccm.201504-0711OC","article-title":"Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis","volume":"193","author":"Tomassetti","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0216","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3343\/alm.2015.35.2.220","article-title":"Clinical usefulness of bronchoalveolar lavage cellular analysis and lymphocyte subsets in diffuse interstitial lung diseases","volume":"35","author":"Lee","year":"2015","journal-title":"Ann Lab Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0217","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.98.12051010","article-title":"Idiopathic nonspecific interstitial pneumonia\/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP [published correction appears in Eur Respir J 1999 Mar;13(3):711]","volume":"12","author":"Nagai","year":"1998","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101484_bib0218","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/rccm.200808-1313OC","article-title":"Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis","volume":"179","author":"Ohshimo","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0219","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12952-017-0069-0","article-title":"The diagnostic value of the bronchoalveolar lavage in interstitial lung diseases","volume":"16","author":"Efared","year":"2017","journal-title":"J Negat Results Biomed"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0220","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1183\/09031936.04.00101303","article-title":"Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases","volume":"24","author":"Welker","year":"2004","journal-title":"Eur Respir J"},{"issue":"128","key":"10.1016\/j.disamonth.2022.101484_bib0221","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1183\/09059180.00001213","article-title":"Managing diagnostic procedures in idiopathic pulmonary fibrosis","volume":"22","author":"Wells","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0222","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1164\/rccm.200402-147OC","article-title":"Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?","volume":"170","author":"Flaherty","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0223","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1164\/rccm.200606-833OC","article-title":"Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?","volume":"175","author":"Flaherty","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0224","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jcm5080066","article-title":"A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre","volume":"5","author":"Chaudhuri","year":"2016","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0225","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/resp.12850","article-title":"Clinical impact of the interstitial lung disease multidisciplinary service","volume":"21","author":"Jo","year":"2016","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0226","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1164\/rccm.201607-1484OC","article-title":"Interstitial Lung Disease in India. Results of a Prospective Registry","volume":"195","author":"Singh","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0227","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1183\/09031936.00063706","article-title":"Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis","volume":"31","author":"Thomeer","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0228","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1746-1596-7-160","article-title":"Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases","volume":"7","author":"Theegarten","year":"2012","journal-title":"Diagn Pathol"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101484_bib0229","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/resp.13694","article-title":"Signals and signposts: Biomarkers in IPF and PAH at the crossroads of clinical relevance","volume":"24","author":"Sullivan","year":"2019","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0230","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.chest.2018.08.1083","article-title":"Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers","volume":"154","author":"Raghu","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0231","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0232","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2174\/138161206775474387","article-title":"Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases","volume":"12","author":"Takahashi","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0233","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201505-0862OC","article-title":"Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias","volume":"194","author":"White","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0234","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/thorax.58.1.52","article-title":"High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia","volume":"58","author":"Ishii","year":"2003","journal-title":"Thorax"},{"issue":"3 Pt 1","key":"10.1016\/j.disamonth.2022.101484_bib0235","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1164\/ajrccm.162.3.9910080","article-title":"Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent","volume":"162","author":"Takahashi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0236","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.rmed.2017.08.021","article-title":"Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"131","author":"Ikeda","year":"2017","journal-title":"Respir Med"},{"issue":"5 Pt 1","key":"10.1016\/j.disamonth.2022.101484_bib0237","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1164\/ajrccm.158.5.9803115","article-title":"Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis","volume":"158","author":"Yokoyama","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0238","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.rmed.2015.06.003","article-title":"Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias","volume":"109","author":"Morais","year":"2015","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0239","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1371\/journal.pmed.0050093","article-title":"MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis","volume":"5","author":"Rosas","year":"2008","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0240","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1378\/chest.11-2735","article-title":"Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis","volume":"143","author":"Song","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0241","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.96.1.68","article-title":"New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6","volume":"96","author":"Kohno","year":"1989","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0242","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1165\/ajrcmb.17.4.2253","article-title":"KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts","volume":"17","author":"Hirasawa","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0243","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","article-title":"Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases","volume":"165","author":"Ohnishi","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0244","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2796.2006.01704.x","article-title":"Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases","volume":"260","author":"Satoh","year":"2006","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0245","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1440-1843.2006.00834.x","article-title":"Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis","volume":"11","author":"Yokoyama","year":"2006","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0246","doi-asserted-by":"crossref","first-page":"00019","DOI":"10.1183\/23120541.00019-2016","article-title":"Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis","volume":"3","author":"Sokai","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.disamonth.2022.101484_bib0247","doi-asserted-by":"crossref","unstructured":"Wakamatsu K, Nagata N, Kumazoe H, et\u00a0al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig. 2017;55(1):16-23. doi:10.1016\/j.resinv.2016.09.003","DOI":"10.1016\/j.resinv.2016.09.003"},{"issue":"6634","key":"10.1016\/j.disamonth.2022.101484_bib0248","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/42716","article-title":"A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells","volume":"387","author":"Adema","year":"1997","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0249","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.rmed.2013.06.004","article-title":"CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases","volume":"107","author":"Cai","year":"2013","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0250","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S2213-2600(18)30185-1","article-title":"Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials","volume":"6","author":"Neighbors","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0251","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18","volume":"173","author":"Prasse","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0252","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200808-1201OC","article-title":"Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis","volume":"179","author":"Prasse","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0253","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0254","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/resp.13707","article-title":"Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis","volume":"25","author":"Akiyama","year":"2020","journal-title":"Respirology"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.disamonth.2022.101484_bib0256","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa066157","article-title":"Telomerase mutations in families with idiopathic pulmonary fibrosis","volume":"356","author":"Armanios","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.disamonth.2022.101484_bib0257","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0701009104","article-title":"Adult-onset pulmonary fibrosis caused by mutations in telomerase","volume":"104","author":"Tsakiri","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0258","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/jmg.2008.057356","article-title":"A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis","volume":"45","author":"Mushiroda","year":"2008","journal-title":"J Med Genet"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0259","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1164\/rccm.200804-550OC","article-title":"Telomere shortening in familial and sporadic pulmonary fibrosis","volume":"178","author":"Cronkhite","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"35","key":"10.1016\/j.disamonth.2022.101484_bib0260","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1073\/pnas.0804280105","article-title":"Short telomeres are a risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Alder","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0261","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-021-01750-3","article-title":"Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF","volume":"16","author":"Bonella","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0262","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1164\/rccm.200810-1534OC","article-title":"Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis","volume":"179","author":"Moeller","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0263","doi-asserted-by":"crossref","first-page":"e8959","DOI":"10.1371\/journal.pone.0008959","article-title":"CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis","volume":"5","author":"Gilani","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0264","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40273-018-0727-1","article-title":"pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","volume":"37","author":"Davis","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0265","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S2213-2600(16)00022-9","article-title":"NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis","volume":"4","author":"Laurenson","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"Suppl 14","key":"10.1016\/j.disamonth.2022.101484_bib0266","doi-asserted-by":"crossref","first-page":"S1740","DOI":"10.21037\/jtd.2019.04.62","article-title":"Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)","volume":"11","author":"Saito","year":"2019","journal-title":"J Thorac Dis"},{"issue":"1-3","key":"10.1016\/j.disamonth.2022.101484_bib0267","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(02)01758-2","article-title":"A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level","volume":"446","author":"Nakazato","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0268","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0269","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(24)38125-X","article-title":"Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"289","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0270","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0271","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/13543784.2020.1773790","article-title":"Richeldi L. pamrevlumab for the treatment of idiopathic pulmonary fibrosis","volume":"29","author":"Sgalla","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0272","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1479972311416382","article-title":"Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients","volume":"8","author":"Schoenheit","year":"2011","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.disamonth.2022.101484_bib0273","article-title":"Timing of onset of symptoms in people with idiopathic pulmonary fibrosis [published online ahead of print, 2017 Oct 11]","author":"Hewson","year":"2017","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0274","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12890-017-0468-5","article-title":"Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries","volume":"17","author":"Maher","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0276","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000490667","article-title":"Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views","volume":"96","author":"Maher","year":"2018","journal-title":"Respiration"},{"issue":"Suppl62","key":"10.1016\/j.disamonth.2022.101484_bib0277","first-page":"PA2199","article-title":"Baseline characteristics of the initial 1461 participants in the Pulmonary Fibrosis Foundation patient registry [abstract]","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0278","series-title":"Poster presented at the European Respiratory Society International Congress","article-title":"What can we learn from idiopathic pulmonary fibrosis registries?","author":"Lodhi","year":"2018"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0279","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","article-title":"Limper AH. Adoption of the Antifibrotic Medications pirfenidone and nintedanib for Patients with Idiopathic Pulmonary Fibrosis","volume":"18","author":"Dempsey","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.disamonth.2022.101484_bib0280","doi-asserted-by":"crossref","DOI":"10.1177\/1479973119879678","article-title":"Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis","volume":"16","author":"LaCamera","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0281","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"Albera","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0282","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","article-title":"nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","volume":"72","author":"Kolb","year":"2017","journal-title":"Thorax"},{"issue":"9779","key":"10.1016\/j.disamonth.2022.101484_bib0283","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0284","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","article-title":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension","volume":"73","author":"Richeldi","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.disamonth.2022.101484_bib0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0286","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0287","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0288","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12890-015-0034-y","article-title":"Comparing new treatments for idiopathic pulmonary fibrosis\u2013a network meta-analysis","volume":"15","author":"Loveman","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0289","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-016-0558-x","article-title":"Treatment of idiopathic pulmonary fibrosis: a network meta-analysis","volume":"14","author":"Rochwerg","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2016.07.009","article-title":"nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"40","author":"Rogliani","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0291","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.chest.2015.11.013","article-title":"Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis","volume":"149","author":"Canestaro","year":"2016","journal-title":"Chest"},{"issue":"3-b Suppl","key":"10.1016\/j.disamonth.2022.101484_bib0292","first-page":"S5","article-title":"Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments","volume":"23","author":"Fleetwood","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0293","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028020964451","article-title":"Systematic Review and Meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis","volume":"55","author":"Di Martino","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0294","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/21556660.2019.1597726","article-title":"Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis","volume":"8","author":"Skandamis","year":"2019","journal-title":"J Drug Assess"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0295","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.disamonth.2022.101484_bib0296","first-page":"OA4501","article-title":"Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice","volume":"46","author":"Nicol","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0297","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"nintedanib with Add-on pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0298","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/jcm9020422","article-title":"nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from pirfenidone Therapy: A Retrospective Case Series Study","volume":"9","author":"Vianello","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0299","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0300","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry","author":"Behr","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0301","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0302","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.581828","article-title":"Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study","volume":"7","author":"Cameli","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0303","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0304","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-021-01714-y","article-title":"Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis","volume":"22","author":"Belhassen","year":"2021","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0305","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12931-021-01857-y","article-title":"pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"22","author":"Marijic","year":"2021","journal-title":"Respir Res"},{"issue":"145","key":"10.1016\/j.disamonth.2022.101484_bib0306","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2017","article-title":"When to start and when to stop antifibrotic therapies","volume":"26","author":"Torrisi","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0307","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/thoraxjnl-2015-207011","article-title":"Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis","volume":"71","author":"Nathan","year":"2016","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0308","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00408-016-9912-1","article-title":"First Data on Efficacy and Safety of nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of \u226450 % of Predicted Value","volume":"194","author":"Wuyts","year":"2016","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0309","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1183\/13993003.00584-2015","article-title":"Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF","volume":"46","author":"Milger","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0310","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","article-title":"Japanese guideline for the treatment of idiopathic pulmonary fibrosis","volume":"56","author":"Homma","year":"2018","journal-title":"Respir Investig"},{"issue":"2 Pt 1","key":"10.1016\/j.disamonth.2022.101484_bib0311","first-page":"646","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0312","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/resp.13065","article-title":"High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias","volume":"22","author":"Arai","year":"2017","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0313","first-page":"385","article-title":"Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a single center experience and literature review","volume":"33","author":"Novelli","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0314","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/CE.S76549","article-title":"pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy","volume":"11","author":"Margaritopoulos","year":"2016","journal-title":"Core Evid"},{"key":"10.1016\/j.disamonth.2022.101484_bib0316","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte","year":"2015","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0317","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4155\/cli.15.27","article-title":"nintedanib: a new treatment for idiopathic pulmonary fibrosis","volume":"5","author":"Cottin","year":"2015","journal-title":"Clin Investig (Lond)"},{"issue":"11 Suppl","key":"10.1016\/j.disamonth.2022.101484_bib0318","first-page":"S183","article-title":"Evaluating new treatment options","volume":"23","author":"Nathan","year":"2017","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0319","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(16)30222-3","article-title":"Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities","volume":"5","author":"King","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0320","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3111\/13696998.2012.680553","article-title":"Burden of illness in idiopathic pulmonary fibrosis","volume":"15","author":"Collard","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.disamonth.2022.101484_bib0321","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.rmed.2017.06.001","article-title":"Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities","volume":"129","author":"Buend\u00eda-Rold\u00e1n","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0322","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.disamonth.2022.101484_bib0323","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0324","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0325","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1440-1843.2009.01547.x","article-title":"Cumulative incidence of and predictive factors for lung cancer in IPF","volume":"14","author":"Ozawa","year":"2009","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0326","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1164\/ajrccm.161.1.9906062","article-title":"Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study","volume":"161","author":"Hubbard","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0327","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1183\/09031936.01.99055301","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis","volume":"17","author":"Park","year":"2001","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0328","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtcvs.2008.07.016","article-title":"Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?","volume":"136","author":"Watanabe","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0329","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00595-010-4384-z","article-title":"Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography","volume":"41","author":"Suzuki","year":"2011","journal-title":"Surg Today"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0330","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1093\/ejcts\/ezs147","article-title":"The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer","volume":"41","author":"Mizuno","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0331","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161437","article-title":"Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis","volume":"11","author":"Koo","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0332","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/JTO.0b013e318216ee6b","article-title":"The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer","volume":"6","author":"Kenmotsu","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.disamonth.2022.101484_bib0333","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13014-016-0637-3","article-title":"The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience","volume":"11","author":"Ono","year":"2016","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0334","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.disamonth.2022.101484_bib0335","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-016-2162-z","article-title":"The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts","volume":"16","author":"Mediavilla-Varela","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0336","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.resinv.2017.09.007","article-title":"Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"56","author":"Miura","year":"2018","journal-title":"Respir Investig"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0337","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00408-007-9004-3","article-title":"Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis","volume":"185","author":"Mermigkis","year":"2007","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0338","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1378\/chest.08-2776","article-title":"Obstructive sleep apnea is common in idiopathic pulmonary fibrosis","volume":"136","author":"Lancaster","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.disamonth.2022.101484_bib0339","doi-asserted-by":"crossref","unstructured":"Mermigkis C, Stagaki E, Tryfon S, et\u00a0al. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis?. Sleep Breath. 2010;14(4):387-390. doi:10.1007\/s11325-010-0336-5","DOI":"10.1007\/s11325-010-0336-5"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0340","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11325-014-1033-6","article-title":"Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Mermigkis","year":"2015","journal-title":"Sleep Breath"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0341","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5664\/jcsm.2758","article-title":"Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis","volume":"9","author":"Kolilekas","year":"2013","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0342","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1378\/chest.128.3.1475","article-title":"Anticoagulant therapy for idiopathic pulmonary fibrosis","volume":"128","author":"Kubo","year":"2005","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0343","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1183\/13993003.02087-2015","article-title":"Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis [published correction appears in Eur Respir J. 2016 Aug;48(2):593]","volume":"47","author":"Kreuter","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0344","first-page":"121","article-title":"The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice","volume":"30","author":"Tomassetti","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0345","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0346","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0347","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000468546","article-title":"Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received pirfenidone","volume":"93","author":"Kreuter","year":"2017","journal-title":"Respiration"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0348","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2213-2600(16)30235-1","article-title":"Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0349","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0350","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1183\/13993003.01204-2015","article-title":"European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers","volume":"47","author":"Bonella","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0351","doi-asserted-by":"crossref","first-page":"00065","DOI":"10.1183\/23120541.00065-2016","article-title":"What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany","volume":"3","author":"van Manen","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.disamonth.2022.101484_bib0352","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12890-015-0145-5","article-title":"The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study","volume":"15","author":"Sampson","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0353","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00408-011-9355-7","article-title":"Specialist palliative care is more than drugs: a retrospective study of ILD patients","volume":"190","author":"Bajwah","year":"2012","journal-title":"Lung"},{"key":"10.1016\/j.disamonth.2022.101484_bib0354","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1183\/13993003.01566-2015","article-title":"Egerod I. The lived experience with idiopathic pulmonary fibrosis: a qualitative study","volume":"47","author":"Overgaard","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.disamonth.2022.101484_bib0355","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12904-016-0158-8","article-title":"End-of-life care of patients with idiopathic pulmonary fibrosis","volume":"15","author":"Rajala","year":"2016","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.disamonth.2022.101484_bib0356","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1513\/AnnalsATS.201306-169ST","article-title":"An official American Thoracic Society workshop report: assessment and palliative management of dyspnea crisis","volume":"10","author":"Mularski","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.disamonth.2022.101484_bib0357","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/bmjspcare-2012-000263","article-title":"I wish I knew more ..\u201d the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals","volume":"3","author":"Bajwah","year":"2013","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.disamonth.2022.101484_bib0358","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2013-000007","article-title":"A qualitative study of informal caregivers\u2019 perspectives on the effects of idiopathic pulmonary fibrosis","volume":"1","author":"Belkin","year":"2014","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.disamonth.2022.101484_bib0359","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/jpm.2016.0258","article-title":"Referral to Palliative Care Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to an Intensive Care Unit","volume":"20","author":"Liang","year":"2017","journal-title":"J Palliat Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0360","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/0269216313497226","article-title":"The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals","volume":"27","author":"Bajwah","year":"2013","journal-title":"Palliat Med"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0361","doi-asserted-by":"crossref","first-page":"331","DOI":"10.12968\/ijpn.2012.18.7.331","article-title":"Palliative and end-of-life care for patients with idiopathic pulmonary fibrosis: challenges and dilemmas","volume":"18","author":"Lewis","year":"2012","journal-title":"Int J Palliat Nurs"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0362","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/082585971403000309","article-title":"Breathing is not an option; dyspnea is","volume":"30","author":"Kalluri","year":"2014","journal-title":"J Palliat Care"},{"key":"10.1016\/j.disamonth.2022.101484_bib0363","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jpainsymman.2016.12.344","article-title":"Early and Integrated Palliative Care to Achieve a Home Death in Idiopathic Pulmonary Fibrosis","volume":"53","author":"Kalluri","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.disamonth.2022.101484_bib0364","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200605-587ST","article-title":"An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses","volume":"177","author":"Lanken","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0365","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/SPC.0b013e3283392b51","article-title":"Management of dyspnea in interstitial lung disease","volume":"4","author":"Ryerson","year":"2010","journal-title":"Curr Opin Support Palliat Care"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0366","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00006199-198605000-00011","article-title":"Hudes M. The sensations of pulmonary dyspnea","volume":"35","author":"Janson-Bjerklie","year":"1986","journal-title":"Nurs Res"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0367","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hrtlng.2003.09.001","article-title":"Correlates of fatigue in Koreans with chronic lung disease","volume":"33","author":"Oh","year":"2004","journal-title":"Heart Lung"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0368","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1183\/09031936.01.17509540","article-title":"Quality of life of idiopathic pulmonary fibrosis patients","volume":"17","author":"De Vries","year":"2001","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0369","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The Burden of Sarcoidosis Symptoms from a Patient Perspective [published correction appears in Lung. 2019 Apr 8;:]","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0370","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ccm.2015.08.013","article-title":"Consequences of Sarcoidosis","volume":"36","author":"Drent","year":"2015","journal-title":"Clin Chest Med"},{"issue":"7362","key":"10.1016\/j.disamonth.2022.101484_bib0371","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/bmj.325.7362.480","volume":"325","author":"Sharpe","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2022.101484_bib0372","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study","volume":"138S","author":"Hendriks","year":"2018","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0373","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00408-019-00234-3","article-title":"Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability","volume":"197","author":"Hendriks","year":"2019","journal-title":"Lung"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0374","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/13696998.2017.1351371","article-title":"Economic burden of sarcoidosis in a commercially-insured population in the United States","volume":"20","author":"Rice","year":"2017","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/kex362","article-title":"Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life","volume":"57","author":"Morrisroe","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0376","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005623.pub2","article-title":"Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases","author":"Bausewein","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0377","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/thoraxjnl-2012-202040","article-title":"Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature","volume":"68","author":"Bajwah","year":"2013","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0378","article-title":"Pulmonary rehabilitation for interstitial lung disease","author":"Dowman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0379","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000486964","article-title":"Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study","volume":"95","author":"Lingner","year":"2018","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0380","doi-asserted-by":"crossref","first-page":"582B","DOI":"10.1378\/chest.132.4_MeetingAbstracts.582b","article-title":"Perception of illness in idiopathic pulmonary fibrosis: a prospective survey of patients and their family members","volume":"132","author":"Vallejo","year":"2007","journal-title":"Chest."},{"issue":"5 Suppl","key":"10.1016\/j.disamonth.2022.101484_bib0381","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.06-2418","article-title":"Pulmonary Rehabilitation: Joint ACCP\/AACVPR Evidence-Based Clinical Practice Guidelines","volume":"131","author":"Ries","year":"2007","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0382","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1378\/chest.113.3.619","article-title":"Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego","volume":"113","author":"Eakin","year":"1998","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0383","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0384","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1378\/chest.127.1.284","article-title":"Health-related quality of life among patients with idiopathic pulmonary fibrosis","volume":"127","author":"Swigris","year":"2005","journal-title":"Chest"},{"issue":"141","key":"10.1016\/j.disamonth.2022.101484_bib0385","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1183\/16000617.0090-2015","article-title":"Cough in idiopathic pulmonary fibrosis","volume":"25","author":"van Manen","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"Suppl 1","key":"10.1016\/j.disamonth.2022.101484_bib0386","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2006.065144","article-title":"British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults","volume":"61","author":"Morice","year":"2006","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0387","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0761-8425(09)74668-6","article-title":"Incontinence urinaire \u00e0 la toux au cours des pneumopathies interstitielles diffuses [Urinary incontinence due to chronic cough in interstitial lung disease]","volume":"26","author":"Bradaia","year":"2009","journal-title":"Rev Mal Respir"},{"issue":"147","key":"10.1016\/j.disamonth.2022.101484_bib0388","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2017","article-title":"Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions","volume":"27","author":"Ferrara","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0389","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-157-6-201209180-00003","article-title":"Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial","volume":"157","author":"Horton","year":"2012","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0390","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1378\/chest.12-2870","article-title":"Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis","volume":"143","author":"Lechtzin","year":"2013","journal-title":"Chest"},{"issue":"9853","key":"10.1016\/j.disamonth.2022.101484_bib0391","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0392","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1465-9921-12-143","article-title":"Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment","volume":"12","author":"Azuma","year":"2011","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0393","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01157-2017","article-title":"Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis","volume":"50","author":"van Manen","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0394","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12890-018-0651-3","article-title":"Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review","volume":"18","author":"Carvajalino","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"8","key":"10.1016\/j.disamonth.2022.101484_bib0395","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/resp.12360","article-title":"Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease","volume":"19","author":"Holland","year":"2014","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0396","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1378\/chest.10-0608","article-title":"Depression and functional status are strongly associated with dyspnea in interstitial lung disease","volume":"139","author":"Ryerson","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0397","doi-asserted-by":"crossref","first-page":"00094","DOI":"10.1183\/23120541.00094-2018","article-title":"Randomised controlled trial of cognitive behavioural therapy in COPD","volume":"4","author":"Heslop-Marshall","year":"2018","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0398","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/thoraxjnl-2014-206583","article-title":"Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention","volume":"70","author":"Bajwah","year":"2015","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0399","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1164\/rccm.201903-0614PP","article-title":"Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease","volume":"200","author":"Wijsenbeek","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0400","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0401","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/bmjspcare-2017-001330","article-title":"Development of tools to facilitate palliative and supportive care referral for patients with idiopathic pulmonary fibrosis","volume":"8","author":"Sharp","year":"2018","journal-title":"BMJ Support Palliat Care"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101484_bib0402","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/jpm.2017.0082","article-title":"Preferred Place of Care and Death in Terminally Ill Patients with Lung and Heart Disease Compared to Cancer Patients","volume":"20","author":"Skorstengaard","year":"2017","journal-title":"J Palliat Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0403","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1378\/chest.14-1127","article-title":"Palliative care and location of death in decedents with idiopathic pulmonary fibrosis","volume":"147","author":"Lindell","year":"2015","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0404","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jpainsymman.2017.10.016","article-title":"Beyond Idiopathic Pulmonary Fibrosis Diagnosis: Multidisciplinary Care With an Early Integrated Palliative Approach Is Associated With a Decrease in Acute Care Utilization and Hospital Deaths","volume":"55","author":"Kalluri","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"21","key":"10.1016\/j.disamonth.2022.101484_bib0405","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Network","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0406","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40266-019-00647-y","article-title":"Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options","volume":"36","author":"Hewitt","year":"2019","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"10.1016\/j.disamonth.2022.101484_bib0407","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.rmed.2010.03.019","article-title":"Bronchoalveolar lavage in idiopathic pulmonary fibrosis: what does it tell us?","volume":"104","author":"Pesci","year":"2010","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101484_bib0408","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd.2017.170","article-title":"Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease [published correction appears in Nat Rev Drug Discov. 2017 Oct 30;16(11):810]","volume":"16","author":"Mora","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.disamonth.2022.101484_bib0409","first-page":"A5169","article-title":"The PROFILE study: a prospective study of fibrosis in lung endpoints to discover and qualify biomarkers for use in clinical trials","volume":"185","author":"Saini","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0410","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000488245","article-title":"C-proSP-B: A Possible Biomarker for Pulmonary Diseases?","volume":"96","author":"Kahn","year":"2018","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0411","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00408-014-9647-9","article-title":"Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias","volume":"192","author":"Korthagen","year":"2014","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0412","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.rmed.2010.09.012","article-title":"Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis","volume":"105","author":"Korthagen","year":"2011","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.disamonth.2022.101484_bib0413","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S2213-2600(17)30349-1","article-title":"Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0414","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201607-1525OC","article-title":"Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis","volume":"196","author":"Huang","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0415","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1164\/rccm.201607-1408OC","article-title":"Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis","volume":"195","author":"Molyneaux","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0416","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.trsl.2012.01.012","article-title":"Peripheral blood biomarkers in idiopathic pulmonary fibrosis","volume":"159","author":"Vij","year":"2012","journal-title":"Transl Res"},{"issue":"10","key":"10.1016\/j.disamonth.2022.101484_bib0417","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1164\/rccm.201701-0254OC","article-title":"Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"196","author":"Armstrong","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0418","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.201509-1753OC","article-title":"Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities","volume":"194","author":"Ho","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0419","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0420","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1038\/s41598-018-23073-3","article-title":"Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0421","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00615-2019","article-title":"Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!","volume":"53","author":"Torrisi","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0422","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.2017161177","article-title":"Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up","volume":"285","author":"Humphries","year":"2017","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0423","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12931-018-0918-5","article-title":"Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity","volume":"19","author":"Clukers","year":"2018","journal-title":"Respir Res"},{"issue":"16","key":"10.1016\/j.disamonth.2022.101484_bib0424","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A common MUC5B promoter polymorphism and pulmonary fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0425","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ajpath.2018.01.009","article-title":"A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84","volume":"188","author":"Gagnon","year":"2018","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0426","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00408-009-9223-x","article-title":"Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis","volume":"188","author":"Ando","year":"2010","journal-title":"Lung"},{"issue":"5","key":"10.1016\/j.disamonth.2022.101484_bib0427","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00059810","article-title":"Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias [published correction appears in Eur Respir J. 2014 Sep;44(3):826]","volume":"37","author":"Okamoto","year":"2011","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0428","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/01902148.2010.538132","article-title":"Differential expression of monocyte\/macrophage- selective markers in human idiopathic pulmonary fibrosis","volume":"37","author":"Desai","year":"2011","journal-title":"Exp Lung Res"},{"issue":"6","key":"10.1016\/j.disamonth.2022.101484_bib0429","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0430","doi-asserted-by":"crossref","unstructured":"Chiba H, Otsuka M, Takahashi H. Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review. Respir Investig. 2018;56(5):384-391. doi:10.1016\/j.resinv.2018.06.001","DOI":"10.1016\/j.resinv.2018.06.001"},{"key":"10.1016\/j.disamonth.2022.101484_bib0431","first-page":"A6790","article-title":"The PROFILE (Prospective Observation of Fibrosis in the Lung Clinical Endpoints) study","volume":"195","author":"Maher","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.disamonth.2022.101484_bib0432","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.disamonth.2022.101484_bib0433","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","article-title":"Two pathways for lysophosphatidic acid production","volume":"1781","author":"Aoki","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.disamonth.2022.101484_bib0434","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1164\/rccm.200810-1596OC","article-title":"Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis [published correction appears in Am J Respir Crit Care Med. 2009 Aug 15;180(4):380]","volume":"180","author":"Konishi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.disamonth.2022.101484_bib0435","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1164\/rccm.201304-0760OC","article-title":"The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis","volume":"188","author":"O'Dwyer","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.disamonth.2022.101484_bib0436","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev.genet.41.110306.130350","article-title":"How shelterin protects mammalian telomeres","volume":"42","author":"Palm","year":"2008","journal-title":"Annu Rev Genet"},{"issue":"3","key":"10.1016\/j.disamonth.2022.101484_bib0437","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1164\/rccm.201805-0825OC","article-title":"Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres","volume":"199","author":"Popescu","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.disamonth.2022.101484_bib0438","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1164\/rccm.201803-0444PP","article-title":"Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis","volume":"199","author":"Wu","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.disamonth.2022.101484_bib0439","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/resp.12569","article-title":"Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers","volume":"20","author":"Hambly","year":"2015","journal-title":"Respirology"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502922001687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502922001687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T01:04:38Z","timestamp":1757898278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502922001687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":439,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0011502922001687"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2022.101484","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2022.101484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101484"}}